Advertisement

Topics

Eli Lilly's new migraine drug succeeds in late-stage study

09:41 EDT 4 Aug 2017 | Fox Business

Eli Lilly and Company announced Friday that its new drug for acute migraines, lasmiditan, has met its primary endpoint in a second Phase 3 study and the company plans to submit for FDA approval during the second half of 2018.

Original Article: Eli Lilly's new migraine drug succeeds in late-stage study

NEXT ARTICLE

More From BioPortfolio on "Eli Lilly's new migraine drug succeeds in late-stage study"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...